Shandong Pharmaceutical Glass Successfully Developed Neutral Medicinal Glass

Shandong Pharmaceutical Glass Co., Ltd. has taken the lead in the development of neutral borosilicate medical glass in China. Recently, it has passed the appraisal from the State Food and Drug Administration and the National Pharmaceutical Packaging Association, and the product fills the domestic gap.

The test results show that the safety performance of Shandong Zhongbo's neutral borosilicate medical glass products is in full compliance with the requirements of the United States Pharmacopoeia and the European Pharmacopoeia, and all indicators have reached and partially exceeded the national standards (YBB) and international ISO standards, and the product quality To reach the international advanced level.

It is understood that medicinal glass is mainly divided into three categories of soda-lime glass, 3.3 borosilicate glass and neutral glass. Neutral glass with excellent chemical stability and thermal stability, currently widely used in the field of international pharmaceutical packaging. Due to technical limitations, the development and production of neutral glass in China has not been able to achieve a breakthrough. The neutral borosilicate medical glass developed by Shandong Pharmaceutical Glass Co., Ltd. uses advanced low-aluminum neutral glass formulation and all-electrofusion production technology. The melting, feeding, forming and inspection packaging of the glass are all controlled automatically and the production technology is achieved. International advanced level. With the use of batches by users, this product fully meets the requirements for the use of drugs such as plasma, vaccines, and biological products.

The general manager of Shandong Pharmaceutical Glass Co., Ltd. Xin Yonggang said: “At present, the domestic market demand for neutral pharmaceutical glass bottles is around 25 million. The company will further increase the research on drug compatibility and market Promotion , expand the production scale, and make the product 2006. It has reached a production scale of 20 million, and it occupies most of the domestic market share.” He also said that the gross profit margin of this product is expected to be around 20%, which is significantly higher than the current company's comprehensive gross profit margin of about 12%.

Shandong Pharmaceutical Glass Co., Ltd. is currently the largest pharmaceutical glass packaging company with the highest level of product quality in China and has a history of more than 30 years. It provides glass bottles for molded pharmaceuticals, medical glass tubes, and ampoules for the domestic and foreign pharmaceutical manufacturers. Pharmaceutical glass bottles, brown bottles, infusion bottles and other six series of more than 200 specifications of products, the company's leading product mold pharmaceutical glass bottles with an annual output of more than 7 billion, domestic market share of more than 70%, products sold in addition to There are more than 700 pharmaceutical companies in all provinces, municipalities and autonomous regions outside Tibet and Taiwan, and some are exported abroad. The company's main users are Harbin Pharmaceutical Group, Northeast Pharmaceuticals, North China Pharmaceuticals, Xinhua Pharmaceuticals and other domestic large-scale antibiotic preparations.

In 2005, the company's annual output of 500 million butyl rubber plug production line projects, lightweight thin-walled high-grade medicinal glass bottles, high-grade biological preparation control bottles, molded bottles and other projects were successively put into production to produce benefits, which ensured that the company's future performance will continue to be stable. increase. Among them, the company's butyl rubber plug project has begun to produce benefits. The business achieved sales of more than 50 million yuan from 1 to 9 months, and the gross profit margin was about 20%. At the same time, the company's high-grade biological preparation bottle and molded bottle project are under intense construction. At present, about 50% of the project's progress has been completed. After it is completed and put into production, it is estimated that the annual sales revenue will increase by 46.4 million yuan and the profit will reach 6.43 million yuan. A new profit growth point.